Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California 

Published

Press Release: Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California

Costa Mesa, Calif.–[February 24, 2026]–Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence,a state of the art78,000 square foot facilitylocatedin Costa Mesa, California. Purpose built to support early clinical programs, the new center expands Avid’s development footprint and strengthens the company’s ability to provide end-to-endservices from cell line development through commercial manufacturing. Designed to accelerate clients’ early development timelines, the facility brings together Avid’s core scientific and technical capabilities including:
  • Cell line development
  • Upstream and downstream processand analyticaldevelopment
  • IND enabling analytical method qualification, and testing
  • Early formulation development and characterization
  • Integrated tech transfer into Avid’s CGMP manufacturing facilities
The Early Phase Center of Excellencewas purpose-built tofurther accentuate Avid’scapabilities, tostreamline early development activities,and enable a seamless transition intofull scale CGMP operations. Thecenterhouses experienced, hands on scientificand manufacturingteams,establishedplatform processes, and harmonized quality systems aligned with Avid’s commercial manufacturing facility. This alignment ensures consistency,eliminatesrework, and provides a smooth progression as programs advance from preclinical throughto commercial supply. “Our new Early-Phase Center of Excellence is purpose-built to help both established pharma and innovative biotech companies move into the clinic faster – in a predictable way, with quality and stability as the foundation. Our mission is to strengthen early drug development here in the U.S., accelerating the journey from scientific discovery to patient impact.”said Kenneth Bilenberg, Chief Executive Officer of Avid Bioservices. “The industry has been asking for a U.S.-baseddevelopment andmanufacturing powerhouse that combines speed, quality, and scientific rigor – and we built it.” The Costa Mesa expansion enhances Avid’s overall capacity to support a wide range of biologics including monoclonal antibodies, recombinant proteins, and other complex modalities. The center’s integrated workflows and technology platforms are engineered to reduce program risk, compress timelines, and ensure phaseappropriate developmentfrom the earliest stages. The new Early Phase Center of Excellence is now fully operational and acceptingnew programs. Learn more here

About Avid

Avid Bioservicesis a global contract development and manufacturing organization (CDMO) specializing in mammalian cell-culture manufacturing. Headquartered in the U.S. with a flawless FDA record, Avid is trusted by biopharmaceutical innovators worldwide for its agility, quality, and ability to navigate complex global regulatory landscapes. With experience supporting both emerging biotech and large multinational pharma companies, Avid provides end-to-end solutionsfromdevelopment through commercial supply. Avid By the Numbers:
  • More than600batches manufactured
  • Over 275commercial batches deliveredto over 90countries
  • 6+ approved commercial products
  • 10 successful pre-approval/pre-license inspections acrossglobalregulatory agencies

Media Contacts

Codi Greene
Director, Brand and Media
Email: [email protected]